N
Nick Daneman
Researcher at Sunnybrook Health Sciences Centre
Publications - 295
Citations - 9578
Nick Daneman is an academic researcher from Sunnybrook Health Sciences Centre. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 38, co-authored 234 publications receiving 5960 citations. Previous affiliations of Nick Daneman include Sunnybrook Research Institute & University of Toronto.
Papers
More filters
Journal ArticleDOI
Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis.
Bradley J Langford,Miranda So,Miranda So,Miranda So,Sumit Raybardhan,Valerie Leung,Duncan Westwood,Derek R. MacFadden,Jean-Paul R. Soucy,Nick Daneman +9 more
TL;DR: To determine the prevalence of bacterial co-infection and secondary infection in patients with confirmed COVID-19, a systematic search of MEDLINE, OVID Epub and EMBASE databases for English language literature from 2019 to April 16, 2020 was performed.
Journal ArticleDOI
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance A Randomized Clinical Trial
Patrick N A Harris,Patrick N A Harris,Patrick N A Harris,Paul A. Tambyah,David C. Lye,David C. Lye,David C. Lye,Yin Mo,Tau H. Lee,Tau H. Lee,Tau H. Lee,Mesut Yilmaz,Thamer H. Alenazi,Yaseen M. Arabi,Marco Falcone,Matteo Bassetti,Elda Righi,Benjamin A. Rogers,Souha S. Kanj,Hasan Bhally,Jon Iredell,Jon Iredell,Marc Mendelson,Tom H. Boyles,David Looke,David Looke,Spiros Miyakis,Spiros Miyakis,Spiros Miyakis,Genevieve Walls,Mohammed Al Khamis,Ahmed Zikri,Amy Crowe,Paul R. Ingram,Paul R. Ingram,Nick Daneman,Paul M. Griffin,Paul M. Griffin,Paul M. Griffin,Eugene Athan,Penelope Lorenc,Peter Baker,Leah W. Roberts,Scott A. Beatson,Anton Y. Peleg,Anton Y. Peleg,Tiffany Harris-Brown,David L. Paterson,David L. Paterson +48 more
TL;DR: Among patients with E coli or K pneumoniae bloodstream infection and ceftriaxone resistance, definitive treatment with piperacillin-tazobactam compared with meropenem did not result in a noninferior 30-day mortality, and findings do not support use of piperACillin- tazobactsam in this setting.
Journal ArticleDOI
Meta-Analysis of Antibiotics and the Risk of Community-Associated Clostridium difficile Infection
TL;DR: Avoidance of high- risk antibiotics in favor of lower-risk antibiotics (such as penicillins, macrolides, and tetracyclines) may help reduce the incidence of CDI.
Journal ArticleDOI
Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis.
Bradley J Langford,Miranda So,Miranda So,Miranda So,Sumit Raybardhan,Valerie Leung,Jean-Paul R. Soucy,Duncan Westwood,Nick Daneman,Derek R. MacFadden +9 more
TL;DR: In this paper, the prevalence and associated factors of antibiotic prescribing in patients with SARS-CoV-2 infection were estimated in a randomized controlled trial with 30,623 patients.
Journal ArticleDOI
Impact of antimicrobial stewardship in critical care: a systematic review
Reham Kaki,Marion Elligsen,Sandra A N Walker,Sandra A N Walker,Andrew E. Simor,Andrew E. Simor,Lesley Palmay,Nick Daneman,Nick Daneman +8 more
TL;DR: In this paper, the authors identified six intervention types: studies of antibiotic restriction or preapproval, formal infectious diseases physician consultation, implementation of guidelines or protocols for de-escalation, guidelines for antibiotic prophylaxis or treatment in intensive care, formal reassessment of antibiotics on a pre-specified day of therapy, and implementation of computer-assisted decision support.